Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years
NCT00783653
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
22
Enrollment
OTHER
Sponsor class
Conditions
Acute Myeloid Leukemia
Interventions
DRUG:
Sunitinib
Sponsor
Universitätsklinikum Hamburg-Eppendorf